Career Enhancement Program (CEP)

职业提升计划（CEP）

• 批准号: 10684244
• 负责人: Cesar M Castro
• 金额: $ 13.1万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-03 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10684244
• 关键词: Achievement; American Association of Cancer Research; Attention; Cancer Center; Career Mobility; Clinical; Collaborations; Consultations; Dana-Farber Cancer Institute; Dedications; Diagnosis; Educational process of instructing; Environment; Extramural Activities; Faculty; Fostering; Funding; Gender; Goals; Grant; Gynecologic Oncology; Hospitals; Individual; Institution; International; Israel; Leadership; Malignant neoplasm of ovary; Measures; Medical center; Mentors; Minority Recruitment; Monitor; New England; Oncology; Outcome; Outcome Measure; Paper; Patients; Peer Review; Persons; Population; Process; Public Health; Publications; Published Comment; Research Personnel; Resources; Secure; Societies; Source; Supervision; Talents; Training; Training Programs; Translating; Translational Research; Work; anticancer research; cancer therapy; candidate selection; career; career development; drug development; ethnic diversity; faculty support; gender diversity; instructor; medical schools; member; novel therapeutics; professor; programs; rapid growth; recruit; senior faculty; success; translational cancer research; translational impact; translational scientist

Project Summary CAREER ENHANCEMENT PROGRAM THE OVERALL OBJECTIVE of the Career Advancement Program will be: to increase the breadth and depth of the ovarian cancer translational investigator pool at the DF/HCC and across the US. We expect to train individuals who will become 2025’s National / International leaders in the pathobiology, diagnosis, treatment and control of Ovarian Cancers. The program will be led by Dr. David Spriggs, one of the overall SPORE PI’s and with the ongoing advice and consultation of Drs D’Andrea and Dr. Steve Cannistra. Dr. Spriggs has a long track record of successful recruiting and mentoring new academic investigators into new drug development and ovarian cancer treatment. The Specific aims will define the Career Enhancement Program: Aim 1. Identify appropriate candidates, primarily junior faculty members seeking to become independent investigators in ovarian cancer research, provide and secure funding for these investigators, and assure SPORE resources for awardees. This group will include applicants from the rich DFHCC pool of fellows and junior faculty as well as candidates from the other New England Institutions, Collaborating SPORE’s and national candidates solicited from AACR and the Society of Gynecologic Oncology. We are particularly committed to increase the diversity of the peer reviewed translational science investigators in ovarian cancer. Selection will rely on the entire SPORE leadership and be confirmed by the EAB. Aim 2. Promote a mentoring environment and plan that will assist the career enhancement and success of the CEP awardees. Through the environment in the DF/HCC, we will create individualized training programs (IDP’s)for every funded junior faculty person and build a team of scientific, clinical and personal mentors around each one; Aim 3. Monitor the scientific and academic progress of the awardees and the program. Particular attention will be given transition points, such as the instructor/assistant professor interface and the attainment of RO1 equivalent funding which will mark transition to full independence. Short term outcome measures will include publication of high impact papers and the submission of extramural peer reviewed funding. Long term outcomes will be persistence in ovarian cancer translational research as measured by continuing peer reviewed publication in ovarian cancer research and achievement of senior faculty status at academic institutions 5-7 years after completion of the CEP completion. The majority of support will come from a variety of institutional sources from the DFHCC, the DFCI, the Beth Israel Deaconess Medical Center and the MGH. Specific plans for the identification, recruitment and mentoring of a diverse awardee pool will incorporate resources for specific gender and minority recruitment efforts from Harvard Medical School and the individual hospitals involved in the SPORE.

项目摘要 职业提升计划 职业发展计划的总体目标是：增加以下方面的广度和深度： DF/HCC和美国各地的卵巢癌转化研究者库。我们希望训练 这些人将成为2025年病理学、诊断、治疗和康复领域的国家/国际领导者。 控制卵巢癌。该计划将由大卫斯普里格斯博士领导，他是整个孢子PI的一员 以及D 'Andrea博士和Steve Cannistra博士的持续建议和咨询。斯普里格斯博士有一个很长的 成功招募和指导新的学术研究人员进入新药开发的跟踪记录 和卵巢癌治疗。具体目标将界定职业提升计划：目标1。 确定合适的候选人，主要是寻求成为独立调查员的初级教员 在卵巢癌研究中，为这些研究人员提供并确保资金，并确保SPORE资源 获奖者。这个小组将包括申请人从丰富的DFHCC池的研究员和初级教师以及 作为其他新英格兰机构的候选人，合作孢子和国家候选人 从AACR和妇科肿瘤学会征集。我们特别致力于增加 卵巢癌的同行评审转化科学研究者的多样性。选择将取决于 整个SPORE领导层，并由EAB确认。目标二。促进辅导环境和计划 这将有助于职业发展和CEP获奖者的成功。通过环境中的 DF/HCC，我们将为每个资助的初级教师创建个性化的培训计划（IDP），并建立 一个由科学、临床和个人导师组成的团队;目标3。监测科学和 获奖者和项目的学术进展。将特别注意过渡点，例如 作为讲师/助理教授接口和达到RO 1同等资金，这将标志着 过渡到完全独立。短期成果措施将包括发表影响力大的论文 以及提交校外同行评审资金。长期结果将是卵巢癌的持续性 卵巢癌研究中持续同行评审出版物衡量的癌症转化研究 并在完成CEP后5-7年在学术机构获得高级教师地位 建成大部分的支持将来自DFHCC， DFCI，贝斯以色列女执事医疗中心和MGH。具体计划为确定、招聘 多样化的获奖者库将纳入特定性别和少数群体的资源 来自哈佛医学院和参与SPORE的各个医院的招聘工作。